文献速递乳腺癌放疗姑息放疗与转移瘤

立体定向体部放疗在未接受根治性手术的浸润性乳腺癌患者中建立局部控制的作用

Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer Not Undergoing Definitive Surgery.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-10-02

研究纳入2015至2022年间21例不能手术的原发性乳腺癌患者(10例转移性、11例IA-IIIC期),共接受23程SBRT(40 Gy/5次,隔日照射)。中位随访14.7个月,6个月局部控制率100%,12、24、36个月均为93.3%,急性毒性G3为8.7%、G4为0%。

要点

  • 不能手术的原发性乳腺癌患者接受SBRT 40 Gy/5次后,6个月局部控制率100%,12至36个月为93.3%。
  • 急性毒性G1 47.8%、G2 4.3%、G3 8.7%、G4 0%,耐受性良好。
  • 区域进展4例(17.4%),远处进展6例(35.3%),作者建议探索改善区域和远处控制的方法。

核心结论

  • 对不能手术的原发性乳腺癌患者行根治性SBRT可获得良好的局部控制且耐受性良好。
  • 考虑到进展模式,作者认为应研究额外方法来改善区域和远处控制。

研究设计与样本

  • 2015年至2022年间,21例不能手术的原发性乳腺癌患者(10例转移性、11例IA-IIIC期)接受了23程针对原发灶的SBRT。
  • 7例为回顾性分析,15例目前正在一项前瞻性研究中入组。
  • SBRT剂量为40 Gy分5次,隔日照射。
  • 急性(≤3个月)和晚期毒性采用不良事件通用术语标准第5版评估,局部控制与总生存采用Kaplan-Meier曲线估计。

主要发现

  • 中位年龄78.4岁(范围45.9-97.3),中位随访14.7个月(范围3.3-70.3)。
  • SBRT前中位指标病灶大小3.1 cm(范围0.5-14.5),计划治疗体积32.4 cc(范围11.5-522.4)。
  • 治疗后中位4.0个月(范围0.6-11.9)首次影像显示指标病灶中位缩小20.8%(范围0%-100%),SUV中位降低65.2%(范围20.8%-100%)。
  • 中位7.8个月第二次随访影像显示肿瘤大小和SUV较SBRT前分别中位降低62%(范围0%-100%)和88%(范围33.3%-100%)。
  • 估计局部控制率6个月为100%,12、24、36个月均为93.3%;1例在SBRT后9.5个月出现局部进展(初始有缓解)。

关键数值与推荐

  • 区域进展4例(17.4%),中位时间SBRT后18.6个月(范围5.2-22.7)。
  • 远处进展6例(35.3%),中位时间2.7个月(范围0.9-16.2)。
  • 估计总生存6个月85.7%,12个月69.6%,24和36个月均为63.8%。
  • 急性毒性发生率G1 47.8%、G2 4.3%、G3 8.7%、G4 0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Surgery is the backbone of breast cancer (BC) treatment. For patients who cannot undergo surgery, improving local control (LC) of the primary tumor is paramount. To that end, this study explored the role of stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Between 2015 and 2022, 21 nonsurgical candidates (10 metastatic, 11 stage IA-IIIC) received 23 SBRT courses to primary BC. Seven were analyzed retrospectively; 15 are currently enrolled in a prospective study. SBRT (40 Gy/5 fractions) was delivered every other day. Follow-up imaging was reviewed. Acute (≤3 months) and late toxicities were evaluated using Common Terminology Criteria for Adverse Events, version 5. LC and overall survival (OS) were estimated using Kaplan-Meier curves. RESULTS: Median age was 78.4 years (45.9-97.3). Median follow-up was 14.7 months (3.3-70.3). Median pre-SBRT index lesion size was 3.1 cm (0.5-14.5) and planning treatment volume was 32.4 cc (11.5-522.4). Initial posttreatment imaging performed at a median 4.0 months (0.6-11.9) post-SBRT demonstrated median decrease in index lesion size of 20.8% (0%-100%); SUV reduction of 65.2% (20.8%-100%). Second follow-up scans at a median 7.8 months post-SBRT showed 62% (0%-100%) and 88% (33.3%-100%) median reduction in tumor size and SUV, respectively, compared with pre-SBRT values. The estimated LC rate was 100% at 6 months and 93.3% at 12, 24, and 36 months. Local progression occurred in 1 case 9.5 months after SBRT, after an initial response. Regional progression occurred in 4 cases (17.4%) at a median 18.6 months (5.2-22.7) post-SBRT. Six patients (35.3%) developed distant progression at a median 2.7 months (0.9-16.2). The estimated OS was 85.7% at 6 months, 69.6% at 12 months, and 63.8% at 24 and 36 months. The rates of acute toxicity were G1: 47.8%, G2: 4.3%, G3: 8.7%, and G4: 0%. CONCLUSIONS: Definitive SBRT for primary BC resulted in good LC in nonsurgical patients and was well-tolerated. Considering the pattern of progression, additional approaches to improve regional/distant control should be investigated.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zabrocka E, Polce S, Roberson JD, et al. Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer Not Undergoing Definitive Surgery. Int J Radiat Oncol Biol Phys. 2023. PMID: 37793576. doi:10.1016/j.ijrobp.2023.08.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。